Third Harmonic Bio Management
Management criteria checks 2/4
Third Harmonic Bio's CEO is Natalie Holles, appointed in Aug 2021, has a tenure of 3.67 years. total yearly compensation is $4.16M, comprised of 14.7% salary and 85.3% bonuses, including company stock and options. directly owns 2.7% of the company’s shares, worth $6.28M. The average tenure of the management team and the board of directors is 2 years and 4.2 years respectively.
Key information
Natalie Holles
Chief executive officer
US$4.2m
Total compensation
| CEO salary percentage | 14.7% |
| CEO tenure | 3.7yrs |
| CEO ownership | 2.7% |
| Management average tenure | 2yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth
Apr 15
Third Harmonic Bio (NASDAQ:THRD) Is In A Good Position To Deliver On Growth Plans
Nov 16Companies Like Third Harmonic Bio (NASDAQ:THRD) Can Afford To Invest In Growth
Aug 03Here's Why We're Not At All Concerned With Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Situation
Apr 06We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
Sep 06We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
May 02We're Not Very Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Rate
Dec 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$4m | US$611k | -US$45m |
| Sep 30 2024 | n/a | n/a | -US$39m |
| Jun 30 2024 | n/a | n/a | -US$33m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$3m | US$608k | -US$31m |
| Sep 30 2023 | n/a | n/a | -US$35m |
| Jun 30 2023 | n/a | n/a | -US$36m |
| Mar 31 2023 | n/a | n/a | -US$36m |
| Dec 31 2022 | US$10m | US$530k | -US$35m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$2m | US$197k | -US$30m |
Compensation vs Market: Natalie's total compensation ($USD4.16M) is above average for companies of similar size in the US market ($USD1.62M).
Compensation vs Earnings: Natalie's compensation has increased whilst the company is unprofitable.
CEO
Natalie Holles (51 yo)
3.7yrs
Tenure
US$4,157,389
Compensation
Ms. Natalie C. Holles serves as Chief Executive Officer since August 9, 2021 and Director of Third Harmonic Bio, Inc. since August 2021. She was an Independent Director at Allakos Inc. since December 2020...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.7yrs | US$4.16m | 2.7% $ 6.3m | |
| Chief Financial & Business Officer | 1.3yrs | US$4.02m | 0% $ 0 | |
| Chief Operating Officer | less than a year | no data | no data | |
| Chief Administrative Officer | 2.8yrs | US$1.11m | no data | |
| Senior Vice President of Development Operations | no data | no data | no data | |
| Chief Medical Officer | 2.8yrs | US$1.38m | no data | |
| Chief Non-Clinical Development Officer | less than a year | no data | no data | |
| Treasurer & Secretary | no data | no data | no data |
2.0yrs
Average Tenure
50.5yo
Average Age
Experienced Management: THRD's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.7yrs | US$4.16m | 2.7% $ 6.3m | |
| Independent Director | 2.8yrs | US$259.14k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$245.14k | no data | |
| Independent Chairman | 4.9yrs | US$280.14k | 0.29% $ 662.5k | |
| Independent Director | 1.1yrs | US$451.98k | 0% $ 0 | |
| Independent Director | 6yrs | US$245.14k | no data | |
| Independent Director | 5.8yrs | US$253.91k | 0.19% $ 441.6k | |
| Non-Employee Supervisor | 1.3yrs | no data | no data |
4.2yrs
Average Tenure
54yo
Average Age
Experienced Board: THRD's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/30 20:33 |
| End of Day Share Price | 2025/04/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Third Harmonic Bio, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akash Tewari | Jefferies LLC |
| Michael Ulz | Morgan Stanley |
| Laura Prendergast | Raymond James & Associates |